{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-180771","form_type":"8-K","ticker":"FBRX","cik":"0001419041","company_name":"Forte Biosciences, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.943939+00:00","generated_at":"2026-05-17T13:01:15.845914+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Forte Biosciences Q2 net loss $0.96/share; $106.1M cash; three FB102 trials on track for 2026 data","bullets":["Net loss per share $(0.96) vs $(6.78) YoY; R&D expenses $8.6M up from $5.7M driven by clinical trials.","Cash and cash equivalents $106.1M; raised $69.9M net in June 2025 offering plus $1.7M overallotment.","Phase 2 celiac disease trial dosing; topline data expected 2026; phase 1b vitiligo data 1H26; alopecia areata initiated with 2026 data.","Shares outstanding: 12.3M common stock and 5.4M pre-funded warrants as of June 30, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-180771","json":"https://secwatch.observer/filing/0001193125-25-180771.json","markdown":"https://secwatch.observer/filing/0001193125-25-180771.md","text":"https://secwatch.observer/filing/0001193125-25-180771.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419041/000119312525180771/0001193125-25-180771-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419041/000119312525180771/d939022d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:01:15.845914+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}